Predictive. Prognostic. Personalized.

Vesta Prostate Risk Stratify is an AI-powered pathology test that assesses prognosis and predicts benefit of triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC). It identifies patients most likely to benefit from intensified treatment based on disease biology, going beyond traditional clinical variables.

The test requires an H&E pathology slide—the most recently available tissue representative of the highest Gleason grade. Acceptable tissue sources include prostate, lymph node, or bone. Valar Labs leverages existing tumor specimens, so no additional biopsy is needed.

Expect results within 2–3 days of sample receipt. Reports are delivered via the secure online portal, and your clinic team is alerted when results are ready.

Your clinic team submits basic patient information via our secure online portal. Valar Labs then coordinates directly with pathology to request the specimen. No complex paperwork is required.

The report classifies patients as Favorable or Unfavorable Risk. Patients classified as Unfavorable Risk benefited from treatment with triplet vs doublet therapy; those with Favorable Risk disease did not. This helps guide personalized treatment intensification decisions.

Vesta is built on Valar Labs’ Computational Histology Artificial Intelligence (CHAI) platform, trained on 500,000+ expert pathologist annotations. The platform analyzes H&E pathology slides using novel biomarker signatures validated with data from thousands of patients.

Yes. The Vesta Prostate Risk Stratify biomarker signature was developed and validated using data from multiple pivotal prospective randomized controlled trials.